STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  
Arbuckle Stuart A  
C/O VERTEX PHARMACEUTICALS INCORPORATED  
50 NORTHERN AVENUE  
BOSTON MA 02210

2. Issuer Name and Ticker or Trading Symbol  
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

3. Date of Earliest Transaction (Month/Day/Year)  
12/13/2023

4. If Amendment, Date of Original Filed (Month/Day/Year)  

5. Relationship of Reporting Person(s) to Issuer  
(X) Director  
10% Owner

6. Individual or Joint/Group Filing (Check Applicable Line)  
Form filed by One Reporting Person  
X Form filed by More than One Reporting Person

Rule 10b5-1(c) Transaction Indication  

X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)  
Common Stock  
Common Stock  
Common Stock

2. Transaction Date (Month/Day/Year)  
12/13/2023  
12/13/2023  
12/13/2023

3. Transaction Code (Instr. 8)  
M  
K(1)  
-

4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)  
8,603  
8,603  
-

5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)  
$187.53  
$399  
-

6. Ownership Code (Instr. 4)  
10  
D  
-

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 5)  
Stock Option (Right to Buy)  
Stock Option (Right to Buy)  
Stock Option (Right to Buy)

2. Conversion or Exercise Price of Derivative Security  
$187.53  
$187.53  
$187.53

3. Transaction Date (Month/Day/Year)  
12/13/2023  
12/13/2023  
12/13/2023

4. Transaction Code (Instr. 8)  
M  
K(2)  
-

5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)  
8,603  
0  
-

6. Date Exercisable and Expiration Date (Month/Day/Year)  
02/05/2029  
-

7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  
Common Stock  
Common Stock  
Common Stock

8. Price of Derivative Security (Instr. 5)  
0  
-

9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)  
0  
-

10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)  
D  
-

11. Nature of Indirect Beneficial Ownership (Instr. 4)  
-

Explanation of Responses:
1. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.
2. Fully vested.

Remarks:

/s/ Christiana Stevenson  
Attorney-in-Fact  
12/15/2023

* Signature of Reporting Person  
Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.